These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32622789)

  • 1. Cost-efficiency analysis of voluntary vaccination against n-serovar diseases using antibody-dependent enhancement: A game approach.
    Kabir KMA; Tanimoto J
    J Theor Biol; 2020 Oct; 503():110379. PubMed ID: 32622789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tetravalent dengue vaccination with screening, ADE, and altered infectivity on single-serotype dengue and Zika transmission.
    Kribs C; Greenhalgh D
    J Math Biol; 2023 Apr; 86(5):85. PubMed ID: 37119296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Bull Math Biol; 2020 Jan; 82(1):12. PubMed ID: 31933012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement.
    Tang B; Huo X; Xiao Y; Ruan S; Wu J
    Theor Biol Med Model; 2018 Sep; 15(1):13. PubMed ID: 30173664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why are dengue virus serotypes so distantly related? Enhancement and limiting serotype similarity between dengue virus strains.
    Kawaguchi I; Sasaki A; Boots M
    Proc Biol Sci; 2003 Nov; 270(1530):2241-7. PubMed ID: 14613610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Impact of Vaccination on the Dynamics of Dengue Infections.
    Knipl D; Moghadas SM
    Bull Math Biol; 2015 Dec; 77(12):2212-30. PubMed ID: 26585748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal dengue vaccination strategies of seropositive individuals.
    Shim E
    Math Biosci Eng; 2019 Feb; 16(3):1171-1189. PubMed ID: 30947414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporary Cross-Immunity as a Plausible Driver of Asynchronous Cycles of Dengue Serotypes.
    Fung T; Clapham HE; Chisholm RA
    Bull Math Biol; 2023 Nov; 85(12):124. PubMed ID: 37962713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinations in disease models with antibody-dependent enhancement.
    Billings L; Fiorillo A; Schwartz IB
    Math Biosci; 2008 Feb; 211(2):265-81. PubMed ID: 17923138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue.
    Adams B; Boots M
    J Theor Biol; 2006 Sep; 242(2):337-46. PubMed ID: 16631802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical and epidemiological survey of the largest dengue outbreak in Southern Taiwan in 2015.
    Wang WH; Lin CY; Chang K; Urbina AN; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Int J Infect Dis; 2019 Nov; 88():88-99. PubMed ID: 31521850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
    Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection severity across scales in multi-strain immuno-epidemiological Dengue model structured by host antibody level.
    Gulbudak H; Browne CJ
    J Math Biol; 2020 May; 80(6):1803-1843. PubMed ID: 32157381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.